Skip to main content

K134 (C09-1141-279)

Aladdin

Catalog No.
C09-1141-279
Manufacturer No.
K647146-10mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $901.08
List Price: $1,001.20

K134 is a phosphodiesterase 3 ( PDE3 ) inhibitor. The IC 50 s of K134 toward PDE3A , PDE3B , PDE5 , PDE2 and PDE4 are 0.1, 0.28, 12.1, >:300 and >:300 µM, respectively.In VitroK134 (K-134) inhibits rat platelet aggregation induced by collagen

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
K134 is a phosphodiesterase 3 ( PDE3 ) inhibitor. The IC 50 s of K134 toward PDE3A , PDE3B , PDE5 , PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.In VitroK134 (K-134) inhibits rat platelet aggregation induced by collagen and ADP in a dose-dependent manner in vitro. The half-maximal (50%) inhibitory concentration (IC 50 ) values of K134 are 2.5 µM and 3.2 µM, respectively. In vitro experiments, K134 also inhibits mouse platelet aggregation induced by collagen and ADP in a dose-dependent manner, and the IC 50 s are 5.5 µM and 6.7 µM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoK134 (K-134) significantly prolongs middle cerebral artery (MCA) occlusion time at doses >10 mg/kg, and reduces cerebral infarct size at 30 mg/kg in the stroke model (n = 12, 87.5±5.6 vs. 126.8±7.5 mm 3 , P<0.01), indicating its potent antithrombotic effect. The overall bleeding risk of K134 is assessed in general in mice. Single oral administration of K134 does not prolong bleeding time at a dose of 30 mg/kg compared to control (106±5 vs. 110±5 s, not significant). Moreover, a sufficiently high enough plasma concentration of K134 (13.6±2.3 µM) is detected to inhibit platelet aggregation at 10 min after single administration in mice at a dose of 30 mg/kg, which is the same time point as the above test of bleeding time. Next, the effects of PDE3 inhibitors on thrombus formation are also investigated in an arteriovenous shunt model in rats. K134 significantly reduces the incidence of occlusive shunt thrombi at doses above 10 mg/kg (half-maximal effective dose: ED 50 =11 mg/kg). The plasma concentration of K134 is 0.43±0.08 µM (C max ) at a dose of 10 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 0.1 µM (PDE3A), 0.28 µM (PDE3B), 12.1 μM (PDE5). Specification: 0.99 Molecular Formula: C22H29N3O4 Molecular Weight: 399.48 PubChem CID: 9908900 Isomeric SMILES: C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
K647146-10mg
CAS:
189362-06-9
Product Size:
10mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.